Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/1756-185X.13913 http://scihub22266oqcxt.onion/10.1111/1756-185X.13913 32881350!7436606!32881350     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Rheum+Dis 2020 ; 23 (8): 1030-1039 Nephropedia Template TP {{tp|p=32881350|t=2020. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients |pdf=|usr=}}{{32881350}} gab.com Text Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients JO: Int J Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=32881350 #FOAvip AIM: To describe the first Australian cases of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) disease (COVID-19) pneumonia treated with the interleukin-6 receptor antagonist tocilizumab. METHODS: Retrospective, open-label, real-world, uncontrolled, single-arm case series conducted in 2 tertiary hospitals in NSW, Australia and 1 tertiary hospital in Victoria, Australia. Five adult male patients aged between 46 and 74 years with type 1 respiratory failure due to COVID-19 pneumonia requiring intensive care unit (ICU) admission and biochemical evidence of systemic hyperinflammation (C-reactive protein greater than 100 mg/L; ferritin greater than 700 mug/L) were administered variable-dose tocilizumab. RESULTS: At between 13 and 26 days follow-up, all patients are alive and have been discharged from ICU. Two patients have been discharged home. Two patients avoided endotracheal intubation. Oxygen therapy has been ceased in three patients. Four adverse events potentially associated with tocilizumab therapy occurred in three patients: ventilator-associated pneumonia, bacteremia associated with central venous catheterization, myositis and hepatitis. All patients received broad-spectrum antibiotics, 4 received corticosteroids and 2 received both lopinavir/ritonavir and hydroxychloroquine. The time from first tocilizumab administration to improvement in ventilation, defined as a 25% reduction in fraction of inspired oxygen required to maintain peripheral oxygen saturation greater than 92%, ranged from 7 hours to 4.6 days. CONCLUSIONS: Tocilizumab use was associated with favorable clinical outcome in our patients. We recommend tocilizumab be included in randomized controlled trials of treatment for patients with severe COVID-19 pneumonia, and be considered for compassionate use in such patients pending the results of these trials. Twit Text FOAVip Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients ????Int J Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=32881350 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32881350 #FOAvip English Wikipedia <ref>{{Cite pmid|32881350}}</ref> Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients #MMPMID32881350 West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K Int J Rheum Dis 2020[Aug]; 23 (8): 1030-1039 PMID32881350show ga AIM: To describe the first Australian cases of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) disease (COVID-19) pneumonia treated with the interleukin-6 receptor antagonist tocilizumab. METHODS: Retrospective, open-label, real-world, uncontrolled, single-arm case series conducted in 2 tertiary hospitals in NSW, Australia and 1 tertiary hospital in Victoria, Australia. Five adult male patients aged between 46 and 74 years with type 1 respiratory failure due to COVID-19 pneumonia requiring intensive care unit (ICU) admission and biochemical evidence of systemic hyperinflammation (C-reactive protein greater than 100 mg/L; ferritin greater than 700 mug/L) were administered variable-dose tocilizumab. RESULTS: At between 13 and 26 days follow-up, all patients are alive and have been discharged from ICU. Two patients have been discharged home. Two patients avoided endotracheal intubation. Oxygen therapy has been ceased in three patients. Four adverse events potentially associated with tocilizumab therapy occurred in three patients: ventilator-associated pneumonia, bacteremia associated with central venous catheterization, myositis and hepatitis. All patients received broad-spectrum antibiotics, 4 received corticosteroids and 2 received both lopinavir/ritonavir and hydroxychloroquine. The time from first tocilizumab administration to improvement in ventilation, defined as a 25% reduction in fraction of inspired oxygen required to maintain peripheral oxygen saturation greater than 92%, ranged from 7 hours to 4.6 days. CONCLUSIONS: Tocilizumab use was associated with favorable clinical outcome in our patients. We recommend tocilizumab be included in randomized controlled trials of treatment for patients with severe COVID-19 pneumonia, and be considered for compassionate use in such patients pending the results of these trials. |Aged[MESH] |Anti-Inflammatory Agents/adverse effects/*therapeutic use[MESH] |Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use[MESH] |Betacoronavirus/*drug effects/pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/diagnosis/*drug therapy/virology[MESH] |Host Microbial Interactions[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |New South Wales[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/virology[MESH] |Retrospective Studies[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH] |Time Factors[MESH] |Treatment Outcome[MESH]Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian(epmc).pdf DeepDyve Pubget Overpricing